In longevity medicine we often talk about the hallmarks of ageing as if they are separate targets: mitochondrial dysfunction over here, cellular senescence over there, epigenetic drift somewhere else, and chronic inflammation sitting in the background. Each one matters. But in my conversation with Dr Elizabeth Yurth, the key message was this: immune ageing may sit upstream of far more of this biology than most people realise.

Her point was not that ageing has one simple cause. Biology is never that tidy. Her argument was that when immune surveillance weakens, the downstream consequences spread everywhere. Senescent cells are not cleared as efficiently. Latent viruses are not held in check as well. The gut barrier becomes more vulnerable. Inflammatory signalling becomes harder to resolve. Repair pathways become less coordinated.

This is why immunosenescence deserves far more attention. It is not simply “a weak immune system.” It is a loss of immune intelligence: the ability to recognise a threat, respond appropriately, resolve the inflammatory response, and return the body to calm.

What immunosenescence really means

Immunosenescence is the progressive deterioration of immune function with age. It includes reduced ability to respond to new infections, poorer immune adaptability, less efficient clearance of senescent and abnormal cells, and a tendency toward chronic low-grade inflammation - often called inflammaging.

Dr Yurth’s clinical warning is that this is not just an old-person problem. She sees younger people with immune systems that look prematurely aged after repeated viral infections, mould exposure, gut disruption, toxin load, severe stress or other cumulative insults. The immune system has a finite bandwidth. The more it is forced to police persistent insults, the less reserve it has for surveillance, repair and regulation.

The Stanford 1000 Immunomes Project gives this conversation a serious scientific foundation. The project recruited around 1,000 people aged 9 to 96 and used deep immune profiling to identify biomarkers of healthy versus dysfunctional immune ageing. From this work came the iAge inflammatory clock, which showed that inflammatory immune signatures can predict multimorbidity, frailty and cardiovascular ageing.

That does not mean CXCL9 is the only marker that matters, or that the immune system is the sole cause of every age-related disease. But it does support the bigger thesis: immune ageing is not a side issue. It is one of the central operating systems of ageing biology.

The thymus: the immune system’s training academy

One of the first places Dr Yurth pointed to was the thymus. In early life, the thymus acts like an immune training academy. It helps educate T cells to distinguish self from non-self, teaching the immune system what to attack and what to tolerate. That education is essential for immune competence and immune restraint.

The problem is that thymic function begins declining early in life. The thymus progressively shrinks and becomes infiltrated with fat, a process called thymic involution. By later adulthood, thymic output is dramatically reduced. That does not mean the immune system stops working, but it does mean the body loses some of the youthful immune education capacity that helps maintain immune precision.

This matters because immune confusion sits behind many modern health problems. When the immune system is undertrained, overburdened or poorly regulated, it can become both weaker and more reactive at the same time. That is the paradox of immune ageing: reduced protection on one side, chronic inflammation and misdirected immune activity on the other.

The viral burden problem

Another major driver is viral burden. Most adults carry latent or persistent viral exposures, including Epstein-Barr virus, cytomegalovirus and herpes viruses. These are not one-and-done events. They remain in the body and require ongoing immune surveillance to keep them contained.

SARS-CoV-2 is different from herpes viruses because it is not a classical latent virus. But persistent viral RNA, protein fragments, immune activation or viral reactivation may play a role in some post-viral syndromes. The broader point is that repeated infections and unresolved immune activation consume immune resources.

Dr Yurth’s framing is simple: if the immune system is constantly occupied putting out old fires, it has less capacity for new threats, repair, barrier maintenance and surveillance of abnormal cells. That is one reason recurrent infections, post-viral symptoms and chronic inflammatory conditions can become such accelerators of biological ageing.

The barrier defence: soldiers at the gate

One of the strongest analogies in the conversation was the castle wall. If your body is a castle, where do you place the soldiers? Not in the courtyard. You place them at the gates and on the walls.

The body’s gates are the mucosal barriers: the gut lining, respiratory mucosa, oral mucosa, reproductive tract, skin, ocular surfaces and even the blood-brain barrier. These are the interfaces where the outside world meets the internal environment. When these barriers are strong, pathogens, toxins and inflammatory triggers are kept where they belong. When they weaken, the immune system is forced into constant response mode.

Secretory IgA is one of the key immune markers at these barriers. It helps trap and neutralise pathogens in the mucus layer before they can penetrate deeper tissues. Low secretory IgA can suggest reduced mucosal defence, which may leave the body more vulnerable to repeated immune triggers.

The gut barrier is especially important. When tight junctions between intestinal cells loosen, bacterial fragments, food antigens and other inflammatory triggers can cross into circulation. That does not automatically mean disease, but it does increase immune workload and can feed systemic inflammation.

Gut integrity is immune integrity

This is why gut health is not a side project in immune ageing. The gut-associated immune system is one of the largest immune interfaces in the body. Antibiotics, chemotherapy, ultra-processed diets, alcohol, infections, mould exposure, some medications and chronic stress can all disturb the microbiome and weaken barrier function.

Probiotics can be useful in the right context, but Dr Yurth’s point was that simply throwing bacteria into a damaged ecosystem is not enough. If the terrain is inflamed, leaky and poorly nourished, introduced strains may not survive or meaningfully shift the system. Prebiotics, fibre, polyphenols, fermented foods and barrier-supportive nutrients often matter just as much, sometimes more.

The bigger question is: how do we help restore the mucosal barrier itself? How do we rebuild immune tolerance and barrier intelligence, not just add more microbes? That is where targeted immune bioactives become interesting.

Targeted bioactives: IDP and the synergy principle

One of the core ingredients discussed in the transcript is Quantec’s IDP. IDP stands for Immune Defense Proteins. It is a New Zealand dairy-derived bioactive whey protein complex that combines lactoferrin, lactoperoxidase, immunoglobulins and more than 50 minor bioactive proteins.

The reason this matters is synergy. The original lactoferrin story is a perfect example. Lactoferrin on its own is well known for antimicrobial and immune effects, but Quantec’s work suggested that the broader protein complex had activity beyond isolated lactoferrin. This fits a pattern we see often in natural-product science: a full-spectrum matrix can behave differently from a single isolated compound.

The evidence base for IDP includes preclinical antiviral and antimicrobial testing, company-supported data and early human research around immune-response support. This is not the same as proving broad disease prevention or treatment. The publishable claim is more precise: IDP provides a concentrated dairy-derived bioactive protein complex with evidence for supporting immune, antimicrobial and barrier-related pathways.

For public-facing copy, I would avoid saying that IDP “kills pathogens,” “outperforms antibiotics,” “prevents COVID,” or “cures SIBO.” The better claim is that IDP appears to support immune defence, gut-barrier resilience and microbial balance through multiple complementary protein fractions.

Immunel and the peptide fraction: supporting immune activation without overactivation

IDP addresses part of the immune-barrier story, but Dr Yurth also wanted to capture more of the peptide and growth-factor signalling side of immune regulation. This is where Immunel becomes relevant. Immunel is rich in proline-rich polypeptides and other immune-active fractions.

Proline-rich polypeptides are interesting because they appear to have immunomodulatory activity rather than simply “stimulating” the immune system in one direction. That matters. A healthy immune system must be able to activate, but it must also resolve. Autoimmunity, chronic inflammation and post-viral syndromes are often not problems of too little immune activity; they are problems of poorly regulated activity.

The Immunel data discussed in the podcast includes cell-based work showing increased phagocytic activity, immune-cell recruitment, NK-cell activation markers such as CD69, synergy with IL-2, and lipoxygenase inhibition. These are relevant pathways. NK cells are part of the body’s first-line defence and immune-surveillance system. Lipoxygenase pathways are involved in inflammatory mediator production.

The careful wording is important: NK activation is not the same as claiming a product treats cancer. Lipoxygenase inhibition is not the same as claiming it replaces anti-inflammatory drugs. The best way to present this is that Immunel appears to support innate immune readiness and inflammatory balance through several biologically plausible pathways.

One correction: the transcript appears to refer to “TGF Alpha 2,” but the biologically plausible term is TGF-beta2. TGF-beta2 is a growth factor/cytokine involved in epithelial and immune signalling. It is not a nucleotide. I would use TGF-beta2 unless your formulation documentation states otherwise.

CXCL9 and carnosic acid: targeting the inflammatory age signal

One of the most compelling parts of the 1000 Immunomes/iAge research is the role of CXCL9. CXCL9 is a chemokine involved in immune-cell trafficking and chronic inflammatory signalling. In the iAge work, it emerged as a strong contributor to inflammatory age and was linked to vascular ageing and endothelial dysfunction.

That makes CXCL9 an attractive target when thinking about immune ageing. In the formulation, carnosic acid from rosemary is included because it has a strong anti-inflammatory and antioxidant profile and has been shown in cell models to influence pathways such as NF-kB, JNK and STAT3. Some research suggests these pathways can influence chemokine expression, including CXCL9-related signalling.

I would avoid calling carnosic acid a proven clinical CXCL9 inhibitor in humans unless you have extract-specific human data. The stronger wording is that carnosic acid was chosen to help address inflammatory signalling pathways linked to immune ageing, including pathways upstream of chemokines such as CXCL9.

Kawakawa: traditional medicine meeting cytokine biology

The final plant Dr Yurth and I discussed was kawakawa, Piper excelsum, a native New Zealand plant with deep roots in Rongoa Maori. It is not kava. It is a different plant, and it has a long history of traditional use for inflammation, digestion, skin issues and general medicinal support.

What makes kawakawa relevant here is not just tradition, but emerging science. Recent human and mechanistic research suggests kawakawa can influence inflammatory gene expression, cytokine signalling and metabolic responses. The transcript discusses IL-10 and NF-kB, which are both central to immune-resolution biology.

A more defensible claim is that kawakawa has emerging evidence for anti-inflammatory and cytokine-modulating effects, and that it was included to support immune resolution - the capacity to calm the inflammatory response after the job is done.

Why Re:juvenate Pro was built this way

This is the logic behind Re:juvenate Pro from Aevum Labs. The formulation was not built as a generic immune booster. It was designed around immunosenescence: barrier integrity, immune surveillance, cytokine balance, innate immune readiness and inflammatory resolution.

The goal is not to suppress the immune system. Suppression is not health. The goal is not to overstimulate it either. The goal is regulation: a system that can respond when it needs to, clean up efficiently, and then return to baseline.

That is the missing piece in so many longevity protocols. We try to raise NAD+. We try to improve mitochondria. We try to clear senescent cells. We try to optimise hormones, methylation and autophagy. But if the immune system is chronically inflamed, barrier-compromised and overloaded by unresolved immune triggers, those downstream interventions may never work as well as they should.

Immune health is not separate from ageing. It is one of the master regulators of ageing.

What this means practically

The first layer is still foundational: sleep, protein, fibre, resistance training, aerobic conditioning, sunlight, stress regulation, metabolic health and reduced toxin exposure where possible. None of that is optional.

But for people dealing with chronic immune stress, recurrent infections, poor recovery, autoimmune tendencies, gut-barrier issues, low secretory IgA, post-viral syndromes or accelerated inflammatory ageing, targeted immune support may be a powerful missing layer.

That is the reason Dr Yurth and I are so focused on immunosenescence. Once the immune system loses its regulatory intelligence, ageing accelerates. Support the immune system well, and you are not just “boosting immunity.” You are supporting the surveillance, repair and resolution systems that every other longevity pathway depends on.

Listen to the podcast here: 

Check out our flagship Immune/gut and longevity supplement aimed at supporting the ageing immune system here: Rejuvenate Pro

·       Stanford 1000 Immunomes Project: https://med.stanford.edu/1000immunomes.html

·       Sayed et al. 2021, iAge inflammatory aging clock, Nature Aging: https://pubmed.ncbi.nlm.nih.gov/34888528/

·       Stanford Cardiovascular Institute summary on CXCL9 and iAge: https://med.stanford.edu/cvi/mission/news_center/articles_announcements/2021/ticking-clock-of-aging.html

·       Liang et al. 2022, Age-related thymic involution review: https://pmc.ncbi.nlm.nih.gov/articles/PMC9381902/

·       Ferrucci and Fabbri 2018, Inflammageing review: https://pmc.ncbi.nlm.nih.gov/articles/PMC6146930/

·       Chen et al. 2023, viral persistence/reactivation and long COVID review: https://pmc.ncbi.nlm.nih.gov/articles/PMC10159620/

·       Quantec IDP product science page: https://www.quantec.co.nz/idp/

·       Immunel white paper, Sterling Technology: https://www.dairyfoods.com/ext/resources/Digital_Brochures/DF-Immunel-White-Paper.pdf?t=1520946123

·       Tautuiaki et al. 2024, anti-inflammatory effects of kawakawa: https://pubmed.ncbi.nlm.nih.gov/39619950/Rejuvenate Pro